Medicaid and GLP-1s in 2026: 13 states cover obesity, 4 dropped out, and the $245 price

Medicaid is fifty programs, and the GLP-1 answer differs by state and by diagnosis. The federal rule fixes the diabetes answer; each state decides the obesity answer, and several changed their minds in the last year.

The federal floor

Under the Medicaid Drug Rebate Program a state must cover a participating manufacturer's drugs for their medically accepted indications, except for the categories section 1927(d)(2) lets a state exclude. Agents used for weight loss are on that list. So:

• Ozempic, the Ozempic pill and Mounjaro for type 2 diabetes: covered in every state, subject to prior authorization and preferred-drug-list placement.
• Wegovy for cardiovascular risk reduction and for MASH, Zepbound for obstructive sleep apnea: covered as FDA-approved indications that are not on the excludable list, again with utilization controls.
• Wegovy, Zepbound, Saxenda or Foundayo for weight management: optional. A state may cover, restrict or exclude.

The state count

KFF's January 16, 2026 brief counts 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service. Five more cover other anti-obesity drugs but not GLP-1s, and 37 do not cover GLP-1s for obesity. Since October 2025 four states have ended obesity coverage: California, New Hampshire, Pennsylvania and South Carolina. North Carolina ended it in October 2025 and reinstated it in December 2025. Every state that covers applies utilization controls: prior authorization with BMI and comorbidity criteria, sometimes step therapy or a lifestyle-program requirement, sometimes reauthorization tied to documented weight loss.

The reason states drop out is arithmetic. A GLP-1 at a net price of several hundred dollars a month across a large eligible population is one of the biggest new line items a state pharmacy budget has faced, and a state that cannot raise revenue mid-year cuts the optional benefit.

The $245 price

The November 6, 2025 agreement between the manufacturers and the federal government made the injectable products (Ozempic, Mounjaro, Wegovy, Zepbound) available to state Medicaid programs at $245 per month for all doses and indications, the same price offered to Medicare, per the AMCP summary. Lilly's release said states would have the ability to expand access to Zepbound and orforglipron through Medicaid. Whether $245 is below what a state already nets after statutory and supplemental rebates is not public, and KFF notes the comparison is unclear. As of the access date the BALANCE model that would have formalised state participation has been postponed indefinitely (see the Medicare page), so the $245 price reaches a state through its own decision to cover, not through a federal program.

What a Medicaid enrollee pays

Medicaid cost sharing is nominal and capped by federal rule; Lilly's Mounjaro pricing information cites copays of about $5 to $11 a month for Medicaid patients. The question is never the copay, it is whether the drug is covered for your diagnosis in your state and whether the prior-authorization criteria are met. Manufacturer savings cards and the self-pay programs are open to Medicaid enrollees only in the sense that anyone can pay cash; the cards themselves exclude government beneficiaries, and the LillyDirect and NovoCare prices apply to anyone with a prescription.

Keeping this page current

State coverage moved four times in the three months before KFF's count. If your state's preferred drug list shows something different from the January 2026 picture, the state document wins; send it to hello@formblends.com and the page will be updated with the date.